TRB 007
Alternative Names: TRB-007Latest Information Update: 17 Feb 2025
At a glance
- Originator Trican Biotechnology
- Class Antineoplastics; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Feb 2025 TRB 007 is still in preclinical trials for Cancer in China (Parenteral) (Trican Biotechnology pipeline, February 2025)
- 26 Mar 2019 Preclinical trials in Cancer in China (Parenteral) before March 2019 (Trican Biotechnology pipeline, March 2019)